Suffolk Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Suffolk Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-25,161	Closed	-$691K	–	147
2018 Q2	$691K	Hold	25,161	–	–	0.1%	100
2018 Q1	$775K	Buy	25,161 +1,500	+6%	+$48.3K	0.11%	100
2017 Q4	$846K	Sell	23,661 -29,436	-55%	-$845K	0.11%	92
2017 Q3	$1.46M	Sell	53,097 -16,998	-24%	-$412K	0.19%	64
2017 Q2	$1.85M	Sell	70,095 -13,400	-16%	-$299K	0.24%	62
2017 Q1	$1.74M	Sell	83,495 -7,699	-8%	-$158K	0.23%	58
2016 Q4	$1.89M	Hold	91,194	–	–	0.26%	62
2016 Q3	$1.48M	Sell	91,194 -67,618	-43%	-$982K	0.2%	92
2016 Q2	$2.16M	Buy	158,812 +62,341	+65%	+$1.1M	0.28%	113
2016 Q1	$1.68M	Buy	96,471 +48,513	+101%	+$987K	0.22%	124
2015 Q4	$1.64M	Buy	+47,958	New	+$1.66M	0.21%	127

Other funds holding RVNC

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

NCM

NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Suffolk Capital Management's RVNC Position: Q3 2018 in Review

Suffolk Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2018, closing a stake of 25,161 shares — an estimated $691K sold.

Suffolk Capital Management first reported a position in RVNC in Q4 2015 and held it in 11 quarters. The position peaked at $2.16M in Q2 2016. 110 funds tracked by Wall St. Rank hold RVNC as of Q3 2018.

Suffolk Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
Suffolk Capital Management sold 25,161 Revance Therapeutics, Inc. shares in Q3 2018, an estimated $691K.
Suffolk Capital Management first reported a position in Revance Therapeutics, Inc. in Q4 2015 and held it in 11 quarters.
Suffolk Capital Management's Revance Therapeutics, Inc. position peaked at $2.16M in Q2 2016.
110 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2018.

Based on Suffolk Capital Management's 13F filing for Q3 2018, filed 9 Nov 2018.